Demonstrates that an oral targeted tilianin nanoplatform reduces plaque progression and oxidative stress in atherosclerotic mice, indicating therapeutic potential for vascular disease.
) mice with atherosclerosis, significant therapeutic effects were observed. The treatment effectively stabilized atherosclerotic plaques. Additionally, FA-Lipo@Til NCs effectively inhibited reactive oxygen species (ROS) production in macrophages, thereby reducing oxidative stress. The treatment also promoted macrophage polarization towards the anti-inflammatory M2 phenotype, enhancing their ability to clear apoptotic cells (efferocytosis) and resolving local inflammation. Notably, throughout the treatment period, significant alterations in blood lipid levels were observed. In summary, FA-Lipo@Til NCs offer a targeted and effective approach to regulate macrophage polarization while also hindering the advancement of atherosclerosis. Besides, our study proposes a promising therapeutic approach for atherosclerosis by leveraging an innovative oral targeted delivery system for BCS IV drugs.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: